GSK plc (NYSE:GSK) Shares Purchased by Choreo LLC

Choreo LLC boosted its position in shares of GSK plc (NYSE:GSK) by 26.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 7,449 shares of the pharmaceutical company’s stock after acquiring an additional 1,570 shares during the period. Choreo LLC’s holdings in GSK were worth $279,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 676 shares in the last quarter. BKM Wealth Management LLC purchased a new position in GSK in the 4th quarter valued at about $32,000. Larson Financial Group LLC boosted its holdings in GSK by 271.8% in the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 647 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after buying an additional 509 shares during the last quarter. Finally, Princeton Global Asset Management LLC increased its stake in GSK by 54.3% during the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after buying an additional 533 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Up 0.4 %

Shares of NYSE:GSK opened at $43.51 on Friday. The business has a 50-day moving average price of $41.85 and a 200 day moving average price of $39.09. GSK plc has a 12-month low of $33.33 and a 12-month high of $43.84. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. The company has a market capitalization of $90.17 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 1.50 and a beta of 0.65.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 14.62% and a return on equity of 52.42%. The company had revenue of $10 billion during the quarter, compared to analysts’ expectations of $9.79 billion. Sell-side analysts expect that GSK plc will post 4.03 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a dividend of $0.3762 per share. This represents a $1.50 dividend on an annualized basis and a yield of 3.46%. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio is 57.61%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Morgan Stanley initiated coverage on shares of GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.